Cellular Therapies and IDRx, crossed the $1 billion mark, a notable decrease from the six seen during the same period last ...
The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback